Last reviewed · How we verify
NCT05719675
Healthcare Intervention Program on Treatment Adherence in People With Newly Diagnosed Type 2 Diabetes Mellitus.
NA trial testing Intervention in Treatment Adherence in 24 participants. Completed in 17 May 2023.
3 March 2023
Quick facts
| Lead sponsor | Universidad Nacional Autonoma de Mexico |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 1 March 2023 |
| Primary completion | 3 March 2023 |
| Estimated completion | 17 May 2023 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Intervention
Conditions studied
- Treatment Adherence — all drugs for Treatment Adherence →
- Quality of Life — all drugs for Quality of Life →
- Glucose Metabolism Disorders (Including Diabetes Mellitus) — all drugs for Glucose Metabolism Disorders (Including Diabetes Mellitus) →
Sponsor
Universidad Nacional Autonoma de Mexico — full company profile →
Who can join
18 and older, any sex, with Treatment Adherence or Quality of Life. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Type 2 Diabetes Mellitus (T2DM) is a group of metabolic disorders characterized by hyperglycemia in the absence of treatment, positioned in the first places of prevalence and mortality in the Mexican population. Adherence to treatment is a central element to prevent complications of the disease, where the active participation of the patient in his or her treatment is fundamental. Despite institutional healthcare efforts to promote this element, there is no clarity in the Clinical Practice Guidelines aimed at the attention of people with T2DM on how to achieve it. The aim of this project will be to evaluate the effect of an intervention based on Contingency Behavior Analysis on treatment adherence, quality of life and glycemic level in people with newly diagnosed T2DM. Pre-experimental design with pretest and posttest measurements. The Dependent Variable will be an intervention based on Contingency Behavior Analysis. The Independent Variables will be adherence to treatment, quality of life and glycemic level. The power calculation suggests an n = 38, using sequential non-probability sampling. People older than 18 years with less than 5 years of T2DM diagnosis will be included. Pretest and posttest differences, effect size and correlations between measurement variables will be analyzed. It is expected that the intervention based on Contingency Behavior Analysis will encourage the active participation of people with T2DM, improving their adherence to treatment, glycemic level and quality of life. Considering that the Clinical Practice Guidelines emphasize the importance of therapeutic adherence through the active participation of the patient and his/her environment, it is expected that this project will provide the tools for behavioral change that so far are not included in public health in Mexico.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05719675
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intervention
Trials testing the same drug.
- NCT07038317 — A Text Messaging Trial to Test Vaping Health Messages Optimized to Young Adults' Vaping Status · NA · not yet recruiting
- NCT06112431 — Eye Health Intervention Study in Upper Manhattan · NA · not yet recruiting
- NCT07202390 — Intraarticular Gold Microparticles for Knee Osteoarthritis · NA · not yet recruiting
- NCT07444736 — Effect of 8 Weeks of Resistance Training With Blood Flow Restriction on Muscle Strength, Clinical Parameters, Biochemica · NA · enrolling by invitation
- NCT07376668 — Effects of a WhatsApp-assisted Prehabilitation for Patient Undergoing Elective Colorectal Cancer Surgery · NA · not yet recruiting
Other recruiting trials for Treatment Adherence
Currently open trials in the same condition.
- NCT06836284 — The Evira Study: Additional Support During Obesity Treatment · NA · recruiting
- NCT06493773 — Alcohol Misuse Treatment to Patients Newly Diagnosed With Alcohol-related Liver Disease: a Randomized Controlled Trial · NA · recruiting
- NCT07144592 — The Effects of a Solution-Focused Approach on Psychosocial Adjustment and Treatment Compliance in Individuals Diagnosed · NA · recruiting
- NCT06621511 — OurSleepKit To Support CPAP Adherence · NA · recruiting
- NCT06373471 — Improving Quality of Life in Older Patients With Frailty and Hematological Cancer Through Geriatric Assessment · NA · recruiting
Other Universidad Nacional Autonoma de Mexico trials
Trials by the same sponsor.
- NCT07252193 — Generative AI-Based Simulation for Diagnostic Communication in Type 2 Diabetes (DIALOGUE-DM2) · NA · completed
- NCT06562387 — tDCS as Adjunctive Therapy to Cognitive Stimulation in Medical Students With Depression · NA · active not recruiting
- NCT05997212 — Effect of Repetitive TMS on Executive Function in Alcohol Use Disorder · NA · recruiting
- NCT06362681 — Effects of Different Remineralization Agents on Molar Incisor Hypomineralization Defects: a Randomized Clinical Study · NA · recruiting
- NCT05852834 — Using YouTube to Learn Anatomy: Perspectives of Mexican Medical Students · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05719675 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad Nacional Autonoma de Mexico
- Last refreshed: 29 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05719675.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing